



Dysregulation of astrocytic Ca²⁺ signaling and gliotransmitter release in mouse models of α -synucleinopathies

Carmen Nanclares¹ · Jonah Poynter¹ · Hector A. Martell-Martinez¹ · Scott Vermilyea^{1,2} · Alfonso Araque¹ · Paulo Kofuji¹ · Michael K. Lee^{1,2} · Ana Covelo^{1,3,4} 

Received: 20 December 2022 / Revised: 17 January 2023 / Accepted: 1 February 2023 / Published online: 10 February 2023
© The Author(s) 2023, corrected publication 2023

Abstract

α -Synuclein is a major component of Lewy bodies (LB) and Lewy neurites (LN) appearing in the postmortem brain of Parkinson's disease (PD) and other α -synucleinopathies. While most studies of α -synucleinopathies have focused on neuronal and synaptic alterations as well as dysfunctions of the astrocytic homeostatic roles, whether the bidirectional astrocyte–neuronal communication is affected in these diseases remains unknown. We have investigated whether the astrocyte Ca²⁺ excitability and the glutamatergic gliotransmission underlying astrocyte–neuronal signaling are altered in several transgenic mouse models related to α -synucleinopathies, i.e., mice expressing high and low levels of the human A53T mutant α -synuclein (G2-3 and H5 mice, respectively) globally or selectively in neurons (iSyn mice), mice expressing human wildtype α -synuclein (I2-2 mice), and mice expressing A30P mutant α -synuclein (O2 mice). Combining astrocytic Ca²⁺ imaging and neuronal electrophysiological recordings in hippocampal slices of these mice, we have found that compared to non-transgenic mice, astrocytes in G2-3 mice at different ages (1–6 months) displayed a Ca²⁺ hyperexcitability that was independent of neurotransmitter receptor activation, suggesting that the expression of α -synuclein mutant A53T altered the intrinsic properties of astrocytes. Similar dysregulation of the astrocyte Ca²⁺ signal was present in H5 mice, but not in I2-2 and O2 mice, indicating α -synuclein mutant-specific effects. Moreover, astrocyte Ca²⁺ hyperexcitability was absent in mice expressing the α -synuclein mutant A53T selectively in neurons, indicating that the effects on astrocytes were cell-autonomous. Consistent with these effects, glutamatergic gliotransmission was enhanced in G2-3 and H5 mice, but was unaffected in I2-2, O2 and iSyn mice. These results indicate a cell-autonomous effect of pathogenic A53T expression in astrocytes that may contribute to the altered neuronal and synaptic function observed in α -synucleinopathies.

Keywords Astrocyte · Calcium · Gliotransmission · α -synuclein · Synucleinopathies

Introduction

Parkinson's disease (PD) and dementia with Lewy Bodies (DLB) are late-onset neurodegenerative diseases characterized by both motor and cognitive symptoms. While the cause of the disease is unknown in most cases, familial

Paulo Kofuji, Michael K. Lee and Ana Covelo have contributed equally.

✉ Paulo Kofuji
kofuj001@umn.edu

✉ Michael K. Lee
mkleee@umn.edu

✉ Ana Covelo
ana.covelo@inserm.fr

¹ Department of Neuroscience, University of Minnesota, 4-125 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA

² Institute for Translational Neuroscience, University of Minnesota, 2101 6th Street SE, Minneapolis, MN 55455, USA

³ Institut National de la Santé et de la Recherche Médicale (INSERM), U1215 NeuroCentre Magendie, 33077 Bordeaux, France

⁴ University of Bordeaux, 33077 Bordeaux, France

PD is caused by abnormalities in selected genes, including the α -synuclein gene (*SNCA*). These abnormalities can be duplication or triplication of the gene [17, 28, 61], but also point mutations, including the A53T [55], A30P [34] and E46K [72]. These and other neurodegenerative dementia in the family of the α -synucleinopathies are characterized by the presence of cytoplasmic inclusions of fibrillary α -synuclein, called Lewy bodies (LB) and Lewy neurites (LN) [64], that are commonly found in neurons but have also been reported in astrocytes [11, 19, 68]. α -Synuclein malfunction may contribute to pathogenesis by disrupting cellular homeostasis, synaptic function and finally inducing neuronal death.

Besides housekeeping functions such as buffering of excess potassium and neurotransmitters in the extracellular space, astrocytes have been implicated in the active regulation of neurotransmission at synapses by the release of neuroactive substances termed gliotransmitters [3, 5, 42, 53, 57, 71]. In this view of a tripartite synapse, astrocytes actively respond to neurotransmitters via receptor-induced Ca^{2+} elevations and, in turn, release gliotransmitters (e.g., glutamate) to have feedback actions on neurons and synapses. The investigations on the role of astrocytes in α -synucleinopathies have been centered on their participation in inflammatory responses and it remains unclear whether astrocyte-neuronal communication and synaptic function are also disrupted.

We report here the properties of astrocyte-neuron communication in different mouse models of early-onset familial PD. Using confocal imaging of astrocyte Ca^{2+} activity in combination with electrophysiological recordings from CA1 pyramidal neurons, we found that A53T mutant α -synuclein markedly alters the intrinsic Ca^{2+} activity of astrocytes as well as their gliotransmitter release. Our results also show that these alterations in astrocyte physiological properties are A53T-mutant specific and do not rely on the neuronal expression of α -synuclein. Thus, our results provide novel insights toward understanding on how α -synucleinopathies can lead to aberrant signaling at a tripartite synapse and suggest a novel mechanism for the synaptic dysfunction observed in these diseases.

Materials and methods

Ethics statement

All of the procedures for handling and sacrificing animals were approved by the University of Minnesota Institutional Animal Care and Use Committee (IACUC) in compliance with the National Institutes of Health guidelines for the care and use of laboratory animals (#1701A34507).

Mouse lines

Mice were housed under 12/12-h light/dark cycle and up to five animals per cage. Males and females 1–6-month-old transgenic mice expressing human wild type (WT) α -synuclein (line I2-2), A53T mutant α -synuclein (lines G2-3 and H5), and A30P mutant α -synuclein (line O2) under the control of a mouse prion protein promoter were used in this study [36]. Transgene negative (TgNg) G2-3 littermates were used as control mice. The generation of these mouse lines has been previously described [36]. Mouse genotype was identified by tail DNA genotyping as previously described [36]. Mice from line G2-3 is available from Jackson Laboratories (B6.Cg-2310039L15Rik^{Tg(Pmp-SNCA*A53T)23Mkle}/J, strain #006,823). In addition, we used mice lacking α -synuclein expression (B6;129X1-*Sncatm1Rosl*/J, Jax strain #003,692).

Conditional transgenic mice expressing A53T mutant human α -synuclein in forebrain excitatory neurons (iSynAT) were generated by mating CamKII α -tTA driver mice (B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ, Jax strain #007004) to Tet-O-h α Syn(A53T) responder mice (Jax: Tg(tetO-SNCA*A53T)E2Cai/J, Jax strain #012443). These iSynAT mice express high levels of transgene expression in forebrain neurons [39].

All mice used were exhaustively backcrossed (at least 10 generations) to C57Bl6/J background and maintained in C57Bl6/J congenic background. The mouse genotype was identified by tail DNA genotyping as previously described [36].

The TgA53T mice (line G2-3) develop subcortical pathology after 10 months of age with very little forebrain pathology [36]. Moreover, these mice do not exhibit any α -synuclein pathology at 6 months of age [60]. In the G2-3 mice, astrocytes in the brainstem and spinal cord are known to harbor α -synuclein pathology along with neuronal pathology [63], but no α -synuclein pathology is seen in cortical or hippocampal astrocytes. In our hands, mice from lines H5, I2-2, and O2 do not develop progressive neurodegenerative disease or overt α -synucleinopathy with aging.

Hippocampal slice preparation

Animals were decapitated and the brain was rapidly removed and placed in ice-cold artificial cerebrospinal fluid (aCSF). Hippocampal slices (350 μm thick) were made with a vibratome and incubated (> 30 min) at room temperature in aCSF containing (in mM): 124 NaCl, 5 KCl, 1.25 NaH_2PO_4 , 2 MgSO_4 , 26 NaHCO_3 , 2 CaCl_2 , and 10 glucose, and was gassed with 95% O_2 /5% CO_2 .

(pH = 7.3–7.4). Slices were transferred to an immersion recording chamber, superfused at 2 ml/min with gassed aCSF, and visualized under an Olympus FV300 laser-scanning confocal microscope or an Olympus BX50WI microscope (Olympus Optical, Japan).

Electrophysiology

Electrophysiological recordings from CA1 pyramidal neurons were made in whole-cell configuration of the patch-clamp technique. Patch electrodes had resistances of 5–10 M Ω when filled with the internal solution containing (in mM): 117 cesium-gluconate, 20 HEPES, 0.4 EGTA, 2.8 NaCl, 5 TEA-Cl, 2 ATP-Mg²⁺, and 0.3 GTP-Na⁺ (pH = 7.3). Recordings were obtained with a PC-ONE amplifier (Dagan Instruments, MN, US) using a DigiData 1440A. Signals were filtered at 1 kHz and acquired at a 10 kHz sampling rate. Membrane potential was held at -70 mV. The pCLAMP 10.4 (Axon Instruments) software was used for data display, acquisition, and storage. Miniature excitatory postsynaptic currents (mEPSCs) and slow inward currents (SICs) were isolated in the presence of tetrodotoxin (TTX, 1 μ M), picrotoxin (50 μ M), and CGP54626 (1 μ M) to block voltage-gated Na⁺ channels, GABA_A, and GABA_B receptors, respectively. Miniature inhibitory postsynaptic currents (mIPSCs) were isolated in the presence of tetrodotoxin (TTX, 1 μ M), CNQX (20 μ M) and AP5 (50 μ M) to block voltage-gated Na⁺ channels, AMPA receptors and NMDA receptors, respectively. Recordings of mIPSCs were performed at a holding voltage of 0 mV.

Ca²⁺ imaging

Ca²⁺ levels in astrocytes located in the *stratum radiatum* of the CA1 region of the hippocampus were monitored using the Ca²⁺ indicator fluo-4. Astrocytes were loaded with the dye by incubating the slices with fluo-4-AM (2 μ M and 0.01% of pluronic) for 45–60 min at room temperature [4, 31, 47, 49, 50]. When fluo-4-positive cells were patched and characterized by their electrophysiological properties they presented typical astrocytes characteristics ($n = 9$), this is, low input resistance, a quasi-linear voltage–current relationship under voltage-clamped conditions and absence of action potentials (Supplementary Fig. 1a–c). On the contrary, recordings from fluo-4-negative cells in the *stratum radiatum* exhibited typical neuronal characteristics ($n = 14$) such as higher input resistances, a non-linear voltage–current curve and fired action potentials (Supplementary Fig. 1d–f). Additionally, slices incubated with fluo-4 and sulforhodamine 101 (SR101), a widely used astrocyte marker known to label astrocytes in the hippocampus [58], provided good co-localization between SR101 and fluo-4-positive cells (Supplementary Fig. 1g). Thus, we conclude that, with the

protocols used in the present study, we analyzed the Ca²⁺ activity of hippocampal astrocytes. Recordings were done in the presence of TTX 1 μ M (unless otherwise indicated) in order to minimize the contribution of neuronal activity to the astrocyte Ca²⁺ activity. Astrocytes were imaged using epifluorescence (Olympus BX50WI microscope) or confocal microscopy (Olympus FV300 laser-scanning confocal microscope; image acquisition rate: 1 Hz). ImageJ software (NIH) was used for quantitative epifluorescence measurements. Ca²⁺ variations recorded at the soma of the cells were estimated as changes of the fluorescence signal over baseline ($\Delta F/F_0$), and cells were considered to show a Ca²⁺ event when $\Delta F/F_0$ increased two times the standard deviation of the baseline. The astrocyte Ca²⁺ signal was quantified from the astrocyte Ca²⁺ event frequency, which was calculated from the number of Ca²⁺ events per min within 10 min of recording. Astrocyte Ca²⁺ events were obtained from 5 to 25 astrocytes in the field of view during the recording.

Primary astrocyte cultures

Cerebral cortices from postnatal day 0–2 mouse pups were dissected out and placed in cold Hibernate-A medium (BrainBits LLC). Cortices were transferred to a digestion medium containing Hibernate-A -CaCl₂ (BrainBits LCC), Papain, l-Cysteine, and EDTA for 12 min at 37°C followed by a wash in a digestion inhibitor solution and gentle trituration. The cells were plated in a growing medium containing DMEM, Sodium Pyruvate, GlutaMax, Penicillin–Streptomycin and Fetal Bovine Serum at a density of 3 million cells per T25 flask. Mixed glia cultures were left growing for at least 10 days. Cultures were then shaken at 200 rpm for 24 h at 37°C. The culture media was then replaced with PBS followed by a 7 min trypsin incubation at 37°C to lift the astrocyte monolayer. For protein analysis, astrocytes were plated in NbAstro (BrainBits LCC), at a density of 100 k cells per well of a Poly-D-Lysine-coated 12-well plate.

Gel electrophoresis and immunoblotting

Primary cortical astrocytes were lysed using ice-cold complete TNE (50 mM Tris–HCl, 150 mM NaCl, 5 mM EDTA, 1% sodium dodecyl sulfate, 0.5% Nonidet P-40, 0.5% sodium deoxycholate) and HALT protease and phosphatase inhibitors (Thermo-Fisher; Waltham, MA). Cell homogenates were sonicated, boiled and centrifuged for 10 min at 16,000 xg. Protein concentration was estimated using BSA assay (Thermo Fisher). Concentration corrected protein samples were diluted in reducing sample buffer (Boston BioProducts), run on 4–20% Criterion TGX gels (Bio-Rad) and transferred onto 0.45 μ m nitrocellulose membranes. Protein on membranes were probed using the following primary antibodies: total α -synuclein (BD Biosciences

610,787), human α -synuclein (HuSyn1) (Made by Lee MK et al., 2002), and α -tubulin (Abcam ab4074). Membranes were visualized using chemiluminescent substrates (Thermo Scientific) and the ImageQuant LAS 4000 detection system (GE Healthcare).

Immunohistochemical staining

Brain tissues were isolated from G2-3 end stage mice as well as TgNg controls and post-fixed in 4% paraformaldehyde for further processing and paraffin embedding. Sections were cut at a thickness of 7 μ m. Immunostaining was performed using the immunoperoxidase method with diaminobenzidine. After deparaffinization followed by antigen retrieval using Reveal Decloaker (Biocare Medical), sections were blocked for 10 min using Background Sniper (Biocare Medical), followed by incubation in primary antibodies (Human-specific α -synuclein, see [36]; GFAP, Synaptic Systems #173–006; GFAP, DakoCytomation Z0334; phospho aS, WAKO, #015–25,191) at 4°C overnight. Sections were then incubated in fluorescent conjugated secondary antibodies for 2 h. Images were captured using a Leica Microsystems Stellaris confocal system.

Statistics

Data are expressed as mean \pm standard error of the mean (s.e.m.). Data normality was assessed using a Kolmogorov–Smirnov statistical test. When data met a normal distribution results were compared using a two-tailed Student's *t*-test ($\alpha=0.05$), One-way ANOVA, or Two-way ANOVA with Tukey method post hoc, otherwise, data were compared using a Mann–Whitney test or Kruskal–Wallis One-Way ANOVA with Dunn's method post hoc. Statistical differences were established with $p < 0.05$ (*), $p < 0.01$ (**) and $p < 0.001$ (***). For the cumulative probability data, results were compared using a two-sample Kolmogorov–Smirnov statistical test using the following equation

$$D_{\alpha} = c(\alpha) \sqrt{\frac{n_1 + n_2}{n_1 n_2}},$$

where D_{α} is the critical D value (maximum difference between the cumulative distributions), n_1 and n_2 are the two samples of sizes and the coefficient is given by the table below.

α	0.10	0.05	0.025	0.01	0.005	0.001
$c(\alpha)$	1.22	1.36	1.48	1.63	1.73	1.95

Drugs and chemicals

Flupenthixol dihydrochloride, CGP54626 hydrochloride, suramin hexasodium salt, AM 251, D-AP5, CNQX disodium salt, LY367385, MPEP hydrochloride, and Tetrodotoxin (TTX) were purchased from Tocris Bioscience. Picrotoxin was purchased from Indofine Chemical Company (Hillsborough, NJ). Fluo-4-AM from Molecular Probes (Eugene, OR). All other drugs were purchased from Sigma.

Results

Astrocyte Ca^{2+} signal is altered in G2-3 transgenic mice

Astrocyte excitability is encoded by fluctuations of cytosolic Ca^{2+} variations that occur spontaneously or in response to neurotransmitters released during neuronal activity [3, 33]. The A53T mutation in the *SNCA* gene is one common cause of early-onset familial PD [55]. To investigate the effects of human A53T-mutant α -synuclein on the spontaneous astrocyte Ca^{2+} activity, we examined the astrocyte Ca^{2+} signals from hippocampal astrocytes in brain slices from 5–6-month-old G2-3 mice (a transgenic mouse line that expresses human α -synuclein with the A53T point

Table 1 Summary of mouse lines

Mouse line	Type of α -synuclein
TgNg	Transgene negative
I2-2	Human wild type α -synuclein
G2-3	High expression levels of human A53T mutant α -synuclein
H5	Low expression levels of human A53T mutant α -synuclein
O2	Human A30P mutant α -synuclein
iSyn	Neuronal expression of human A53T mutant α -synuclein
SynKO	α -synuclein knockout

Mouse lines used in this study and their expression of α -synuclein

mutation, Table 1) [36] and from their transgene negative littermates (TgNg). Hippocampal slices were loaded with the Ca^{2+} indicator Fluo-4, and astrocytes in the CA1 region were imaged for 10 min. Because astrocytes can respond to neurotransmitters released by neurons [3, 33, 71], to minimize neuronal contribution to the astrocyte Ca^{2+} activity, experiments were performed in the presence of tetrodotoxin (TTX 1 μM) which inhibits the firing of action potentials by blocking voltage-gated sodium channels. We found that the astrocyte Ca^{2+} event frequency (calculated as the number of Ca^{2+} events per minute) was significantly higher in astrocytes from the G2-3 transgenic mice (0.76 ± 0.07 events per minute, $n = 93$ astrocytes from $n = 10$ slices; Fig. 1a-c) than those from the TgNg mice (0.42 ± 0.05 events per minute, $n = 68$ astrocytes from $n = 9$ slices, $p = 0.007$; Fig. 1a-c). Interestingly, these changes in astrocyte Ca^{2+} event frequency were present in animals as young as 1 month of age

(Fig. 1d), indicating that the astrocyte signal is altered in G2-3 mice early in their lifespan.

Astrocytes express a variety of receptors that allow them to respond to neurotransmitters with Ca^{2+} increases [2, 3, 21, 22, 27, 41, 45, 48, 52, 53, 70, 71]. We next investigated the possibility that the increase in astrocyte Ca^{2+} event frequency observed in the G2-3 mice is a readout of an increase in neurotransmitter release. To test this possibility, we first monitored astrocyte Ca^{2+} activity in the presence of a cocktail of neurotransmitter receptor antagonists containing CNQX 20 μM , AP5 50 μM , MPEP 50 μM , LY367385 100 μM , picrotoxin 50 μM , CGP54626 1 μM , atropine 50 μM , CPT 10 μM , suramin 100 μM , flupenthixol 30 μM and TTX 1 μM to block glutamatergic, GABAergic, cholinergic, purinergic and dopaminergic transmission. Under these conditions, astrocyte Ca^{2+} event frequency was still increased in G2-3 mice (0.77 ± 0.07 events per minute,




Fig. 1 Astrocyte Ca^{2+} signal is altered in G2-3 transgenic mice. **a** Pseudocolor images and representative traces of Ca^{2+} fluorescence intensities obtained from transgene negative (TgNg) and G2-3 mice. **b** Heat map indicating Ca^{2+} levels and raster plot indicating Ca^{2+} events along time obtained from TgNg and G2-3 mice. **c** Ca^{2+} events

per minute obtained from TgNg and G2-3 mice in control conditions and in the presence of a cocktail of antagonists. **d** Ca^{2+} events per minute obtained from TgNg and G2-3 mice at different ages. Data are expressed as mean \pm s.e.m. (**) $p < 0.01$, (***) $p < 0.001$


$n = 87$ astrocytes from $n = 8$ slices, $p = 0.007$; Fig. 1c) indicating that the increase in astrocyte Ca^{2+} activity is not due to changes in synaptic signaling. This result is further supported by the observation that both the amplitude and frequency of mEPSCs recorded from CA1 pyramidal neurons are decreased in G2-3 mice compared to their TgNg littermates (amplitude: 10.2 ± 1.4 and 6.32 ± 0.9 pA in TgNg and G2-3 mice, respectively, $p = 0.033$. Frequency: 0.32 ± 0.09 and 0.11 ± 0.03 Hz in TgNg and G2-3 mice, respectively, $p = 0.013$; $n = 9$ and $n = 9$ in TgNg and G2-3 mice; Fig. 2a–c) [69], indicating that an increase in the excitatory synaptic activity cannot account for the increase in the astrocyte Ca^{2+} event frequency. Finally, we studied the possibility of an alteration in the inhibitory synaptic transmission. We observed no change in neither the amplitude nor the frequency of mIPSCs recorded from CA1 pyramidal neurons

of G2-3 mice and TgNg littermates (amplitude: 10.44 ± 1.22 and 11.27 ± 0.97 pA in TgNg and G2-3 mice, respectively, $p = 0.505$. Frequency: 0.47 ± 0.07 and 0.45 ± 0.10 Hz in TgNg and G2-3, respectively, $p = 0.856$; $n = 13$ and $n = 13$ in TgNg and G2-3 mice; Fig. 2d–f). These data indicate that the observed increase in astrocyte Ca^{2+} activity in G2-3 mice is not due to an increase in neurotransmission.

Astrocyte Ca^{2+} signal alterations are A53T mutant-specific

In neurons, increased expression of α -synuclein per se cause presynaptic inhibition of neurotransmitter release while only A53T mutant α -synuclein causes postsynaptic deficits [69]. Thus, we next investigated whether the observed differences in astrocyte Ca^{2+} event frequency were specific for the

Fig. 2 The increase in astrocyte Ca^{2+} event frequency observed in the G2-3 mice is not a consequence of an increase in neurotransmitter release. **a** mEPSC traces recorded from TgNg and G2-3 mice. **b** mEPSC amplitude and frequency obtained from TgNg and G2-3 mice. Data are expressed as mean \pm s.e.m. (* $p < 0.05$). **c** Cumulative probability of mEPSC amplitude (left; the maximum difference between the cumulative distributions, D , is 0.44781 with a corresponding $p < 0.001$) and mEPSC frequency (right; the maximum difference between the cumulative distributions, D , is 0.74444 with a corresponding $p < 0.001$). **d** mIPSC traces recorded from TgNg and G2-3 mice. **e** mIPSC amplitude and frequency obtained from TgNg and G2-3 mice. Data are expressed as mean \pm s.e.m. **f** Cumulative probability of mIPSC amplitude (left; the maximum difference between the cumulative distributions, D , is 0.09153 with a corresponding $p > 0.1$) and mIPSC frequency (right; the maximum difference between the cumulative distributions, D , is 0.17188 with a corresponding $p > 0.1$)




A53T mutant α -synuclein or to the overexpression of human α -synuclein in general. To do this, we first used the I2-2 mouse line that expresses a human WT form of α -synuclein (Table 1) [36, 69]. We found that the astrocyte Ca^{2+} event frequency in slices obtained from I2-2 mice was not significantly different from that of TgNg mice (0.32 ± 0.03 events per minute, $n = 65$ astrocytes from $n = 10$ slices; Fig. 3), indicating that the observed changes in astrocyte Ca^{2+} event frequency in G2-3 mice were probably due to the A53T mutation. To further test this hypothesis, we used a transgenic mouse line (H5) that expresses lower levels of human A53T-mutant α -synuclein than the G2-3 mouse line (Table 1) [36, 69]. We observed that the astrocyte Ca^{2+} event frequency was increased when compared with TgNg mice

(0.73 ± 0.06 events per minute, $n = 89$ astrocytes from $n = 10$ slices, $p < 0.001$; Fig. 3) and was similar to that observed in G2-3 mice (Fig. 3). Altogether, these data suggest that the observed increase in astrocytic Ca^{2+} event frequency in the G2-3 transgenic mice was not due to the overexpression of human α -synuclein, but was probably due to the presence of the A53T mutation.

We next explored whether other types of mutant α -synucleins also related to familial PD induce similar changes in the astrocytic Ca^{2+} event frequency. To do this, we analyzed the astrocyte Ca^{2+} signal in the O2 transgenic mice, which expresses human α -synuclein with the A30P mutation (Table 1). We previously showed that despite very high levels of expression, A30P mutant do not cause

Fig. 3 Astrocyte Ca^{2+} alterations are A53T-mutant specific. **a** Representative Ca^{2+} traces, heat maps and raster plots obtained from astrocytes in I2-2, H5 and O2 mice. **b** Ca^{2+} events per minute obtained from TgNg, I2-2, G2-3, H5 and O2 mice. Data are expressed as mean \pm s.e.m. (***) $p < 0.001$




postsynaptic deficits in neurons [69]. The astrocytic Ca^{2+} event frequency in these mice was not significantly different than that of the TgNg mice (0.46 ± 0.06 events per minute, $n = 49$ astrocytes from $n = 10$ slices, $p = 0.842$; Fig. 3), suggesting that the observed increase in astrocytic Ca^{2+} event frequency in the transgenic mice from G2-3 and H5 lines was A53T mutation-specific.

Astrocyte glutamate release is increased in G2-3 transgenic mice

Astrocytes release neuroactive substances, called gliotransmitters [71], which regulate synaptic transmission and neuronal excitability [3, 18, 21, 26, 49, 53]. We next examined whether gliotransmitter release is also altered in G2-3 transgenic mice. To do this, we performed electrophysiological recordings of CA1 pyramidal neurons from G2-3 transgenic and TgNg littermates, and monitored the presence of the NMDA receptor-mediated slow inward currents (SICs), as a biological assay for astrocytic glutamate release [3, 22, 23, 25, 44, 59] (Fig. 4a). SICs were distinguished from mEPSCs by their significantly slower kinetics as previously described

[23, 51] (Fig. 4b). We found an increase in SICs frequency in G2-3 transgenic mice (1.54 ± 0.28 SICs per minute, $n = 9$ neurons) compared to TgNg mice (0.36 ± 0.06 SICs per minute, $n = 7$ neurons, $p = 0.007$; Fig. 4c–e), with no changes in SICs duration (195.68 ± 37.17 ms and 194.07 ± 63.86 ms in G2-3 and TgNg mice, respectively; $p = 0.302$) or amplitude (7.56 ± 1.34 pA and 9.53 ± 2.36 pA in G2-3 and TgNg mice, respectively; $p = 0.992$). Similarly, we found that SICs frequency was also increased in slices obtained from H5 mice, which expresses lower levels of human A53T-mutant α -synuclein [36] (1.29 ± 0.16 SICs per minute, $n = 9$ neurons, $p = 0.008$; Fig. 4d, e). On the contrary, we did not find changes in SICs frequency in the I2-2 mice (0.49 ± 0.08 SICs per minute, $n = 9$ neurons; Fig. 4d, e), that overexpress human WT α -synuclein, or in O2 mice (0.43 ± 0.1 SICs per minute, $n = 10$ neurons; Fig. 4d, e), which express human α -synuclein with the A30P mutation. Altogether, these data indicate that glutamate release from astrocytes is increased in an A53T-mutant specific manner. These results are in line with the observation that Ca^{2+} event frequency is also increased in G2-3 and H5 mice, but not in I2-2 and O2 mice (see Fig. 3).

Fig. 4 Astrocytic glutamate release is increased in G2-3 mice. **a** Scheme of the experimental approach. Note the glutamate (red) release by astrocytes (blue) and the recording CA1 pyramidal neuron (light green). **b** Representative SIC and mEPSC traces. **c** Representative SIC traces (shaded in blue) obtained from TgNg and G2-3 mice. **d** SICs per minute obtained from TgNg, I2-2, G2-3, H5 and O2 mice. Data are expressed as mean \pm s.e.m. (**) $p < 0.01$. **e** Cumulative SIC frequency obtained from TgNg, I2-2 (the maximum difference between the cumulative distributions from TgNg and I2-2 mice, D , is 0.064902 with a corresponding $p > 0.1$), G2-3 (the maximum difference between the cumulative distributions from TgNg and G2-3 mice, D , is 0.386869 with a corresponding $p > 0.1$), H5 (the maximum difference between the cumulative distributions from TgNg and H5 mice, D , is 0.516783 with a corresponding $p > 0.05$) and O2 (the maximum difference between the cumulative distributions from TgNg and O2 mice, D , is 0.067116 with a corresponding $p > 0.1$) mice



Alterations in astrocyte–neuron communication are not mediated by neuronal α -synuclein

Predominant expression of transgenic α -synuclein in neurons of G2-3 model would suggest that neuronal α -synuclein may impact astrocytes, potentially by releasing α -synuclein oligomers that impact astrocyte function [40, 56]. However, expression of mutant α -synuclein in astrocytes from G2-3 model raises the possibility that abnormal α -synuclein in astrocytes causes dysregulation of astrocyte-to-neuronal signaling. To test this hypothesis, we next investigated whether astrocyte–neuron signaling is altered in the transgenic mouse line that specifically overexpresses human A53T-mutant α -synuclein in forebrain excitatory neurons (iSyn mice, Table 1). We recorded astrocyte Ca^{2+} signals and SICs in slices obtained from iSyn mice and we found no difference in astrocytic Ca^{2+} event frequency between the iSyn transgenic mice (0.54 ± 0.053 events per minute, $n = 105$ astrocytes from $n = 17$ slices) and their TgNg littermates (0.53 ± 0.03 events per minute, $n = 148$ astrocytes from $n = 16$ slices, $p = 0.24$; Fig. 5a, b). In addition, we did not find a difference in SICs frequency in iSyn mice (0.5 ± 0.09 SICs per minute, $n = 9$) when compared to their TgNg littermates (0.46 ± 0.11 SICs per minute, $n = 8$, $p = 0.832$; Fig. 5c, d). Interestingly, mEPSC amplitude and frequency were still reduced in iSyn mice (Amplitude: 9.33 ± 0.72 and 7.38 ± 0.47 pA in TgNg and iSyn mice, respectively, $p = 0.036$. Frequency: 0.42 ± 0.07 and 0.14 ± 0.03 Hz in TgNg and iSyn mice, respectively, $p = 0.002$; $n = 8$ and $n = 9$ in TgNg and iSyn mice, respectively; Fig. 5c, e, f). These data suggest that, although neuronal deficits are still present, the enhanced astrocyte–neuron signaling observed in the G2-3 mice is not mediated by the transfer of α -synuclein aggregates from neurons to astrocytes.

Collectively, our results suggest that neuronal expression of the A53T mutant α -synuclein is not sufficient to alter astrocyte–neuron communication. Thus, we tested if the transgene in the G2-3 model is expressed in astrocytes. Specifically, while transgene in the G2-3 model is highly expressed in neurons, the promoter used (moPrp) can drive expression in non-neural tissues [9] and mouse Prp is expressed in glial cells [43]. To determine if A53T mutant human α -synuclein is expressed in astrocytes, we established primary cultures of astrocytes from G2-3 and TgNg mice, along with α -synuclein knockout mice (SynKO), and performed immunoblot analysis for α -synuclein expression. We show that α -synuclein is expressed in astrocytes from TgNg and G2-3, but not SynKO mice (Fig. 6a, b). Using human α -synuclein specific antibody, we also verified that human α -synuclein expression is expressed by G2-3 astrocytes, albeit at much lower levels than in neurons (data not shown). We also demonstrate the presence of human α -synuclein inside G2-3 astrocytes, but not TgNg hippocampal astrocytes

in the *stratum radiatum* (Fig. 6c) and the *dentate gyrus* (Supplementary Fig. 2). Based on these results, we propose that abnormal α -synuclein in astrocytes causes the dysregulation of astrocyte-to-neuronal signaling.

Discussion

α -synucleinopathies are characterized by abnormalities in α -synuclein that lead to synaptic dysfunction, neuronal loss and motor and cognitive deficits. While the effects of α -synuclein on neurons have been studied extensively, its effect on astrocyte physiology remains largely unknown. Here, we investigated the impact of human A53T-mutant α -synuclein on astrocyte–neuron communication. Our results showed that both astrocyte Ca^{2+} activity and gliotransmission were enhanced in mice expressing human A53T-mutant α -synuclein but not in mice expressing human WT or A30P-mutant α -synuclein, indicating that specifically, the A53T point mutation exacerbates astrocyte–neuron signaling. Interestingly, these alterations in astrocyte–neuron communication were independent of neurotransmission and were not present in mice expressing human A53T-mutant α -synuclein exclusively in neurons, suggesting a cell-autonomous effect of A53T-mutant α -synuclein in astrocyte Ca^{2+} signaling and gliotransmitter release.

Unlike neurons, astrocytes are non-electrically excitable cells; instead, astrocyte excitability is encoded by Ca^{2+} fluctuations that occur spontaneously but also in response to neighboring neuronal activity [3, 21, 48]. Our results show that astrocyte Ca^{2+} activity from mice that express human A53T-mutant α -synuclein is altered independently of neurotransmission indicating that A53T mutant α -synuclein directly impacts the intrinsic Ca^{2+} activity of astrocytes. Previous evidence has shown that α -synuclein aggregation produces long-lasting Ca^{2+} transients in cultured neurons [7, 15, 16, 38] and astrocytes [1]. Although both WT and mutant forms of α -synuclein can self-aggregate at high concentrations, the A53T mutant form can aggregate with faster kinetics [6, 37], suggesting that the observed Ca^{2+} alterations may be due to the efficient formation of A53T-mutant α -synuclein aggregations. Even though the specific mechanism remains to be elucidated, our results demonstrate that the A53T-mutant α -synuclein alters the astrocyte Ca^{2+} signal in situ, adding up to other studies showing dysfunctional astrocyte Ca^{2+} signaling in various neurological disorders, including other models of PD [10], Alzheimer's disease (AD) [20, 24, 35, 65] and Huntington's disease [29].

Astrocytes regulate synaptic transmission and neuronal excitability by releasing gliotransmitters [3]. Glutamate released from astrocytes enhances postsynaptic excitability and neuronal coordination by activating extrasynaptic NMDA receptors and inducing SICs [3, 22, 23, 25, 44, 59].




Fig. 5 Astrocyte–neuron signaling is not altered by neuronal α -synuclein. **a** Representative Ca^{2+} fluorescence traces obtained from TgNg and iSyn mice (left), heat maps indicating Ca^{2+} levels from TgNg and iSyn mice (middle), raster plots indicating Ca^{2+} events from TgNg and iSyn mice (right). **b** Ca^{2+} events per minute obtained from TgNg and iSyn mice. **c** Representative SIC (shaded in blue) and mEPSC traces obtained from TgNg and iSyn mice. **d** SICs per minute obtained from TgNg and iSyn mice (left), cumulative SIC frequency obtained from TgNg and iSyn mice (right; the maximum


difference between the cumulative distributions, D , is 0.074561 with a corresponding $p > 0.1$). **e** mEPSC amplitude (left) and cumulative amplitude (right; the maximum difference between the cumulative distributions, D , is 0.22012 with a corresponding $p < 0.001$) obtained from TgNg and iSyn mice. **f** mEPSC frequency (left) and cumulative frequency (right; the maximum difference between the cumulative distributions, D , is 0.58571 with a corresponding $p < 0.025$) obtained from TgNg and iSyn mice. Data are expressed as mean \pm s.e.m. (*) $p < 0.05$ and (**) $p < 0.01$

Abnormal release of glutamate and GABA from astrocytes has been observed in models of AD contributing to enhanced neuronal excitability, synapse loss, synaptic plasticity deficits, and memory impairment [24, 30, 54, 66]. Our results show that SICs frequency was enhanced in mice expressing human A53T-mutant α -synuclein, indicating that astrocyte–neuron signaling is also increased in α -synucleinopathies. No changes in SIC frequency were found in mice expressing human WT or A30P-mutant α -synuclein, suggesting

that the increased gliotransmission may be also linked to the high aggregation potential of the A53T-mutant form of α -synuclein [6].

α -synuclein is a cytosolic protein that can associate with the plasma membrane and is enriched in presynaptic terminals. Through its interaction with the SNARE complex and other presynaptic proteins [12–14], α -synuclein supports synaptic function and suppresses vesicle release by depleting the recycling and readily releasable pools of synaptic

Fig. 6 Analysis of α -synuclein expression in astrocytes. Lysates from primary astrocyte cultures from brains of SynKO, TgNg and G2-3 mice were analyzed for α -synuclein expression. **a** Immunoblot for α -synuclein from brain samples from SynKO, TgNg and G2-3 mice. α -tubulin is used as a loading control. Note that G2-3 astrocytes show strong α -syn reactivity (arrow). α -syn is present in TgNg astrocytes but not in SynKO astrocytes. *Non-specific band. **b** α -synuclein protein levels quantified from a. Data was normalized to α -tubulin levels and relativized to TgNg. **c** Astrocytes within the *stratum radiatum* of G2-3 mice, but not TgNg mice, contain intracellular human α -syntransgenic negative; TgNg glial fibrillary acidic protein, GFAP human alpha-synuclein, HuSyn. Scale bar = 25 μ m



vesicles [46]. In addition, human A53T-mutant α -synuclein also causes postsynaptic and memory deficits by its interaction with the microtubule-associated protein tau [60, 69]. The results reported here show that, in addition to the pre- and postsynaptic deficits, A53T-mutant α -synuclein promotes chronic glutamate release from astrocytes. The hyperfunction of extrasynaptic NMDARs promoted by astrocytic glutamate release may cause neuronal excitotoxicity as postulated to many neurodegenerative diseases. In addition, the dysregulated gliotransmitter release may influence the spatiotemporal dynamics of neuronal networks and thus contributing to the pathology observed in α -synucleinopathies.

While α -synuclein is abundantly expressed in neurons, studies show that astrocytes express low levels of SNCA [8, 32, 62, 67, 73]. In addition to evidence of astrocyte expression of α -synuclein [62, 67], α -synuclein-positive inclusions have been found in astrocytes in postmortem PD brains [8]. Here, we show that astrocytes from G2-3 mice express much higher levels of α -synuclein than normal (see Fig. 6). While the very high levels of human α -synuclein expression could contribute to the abnormal astrocyte neurotransmission, increased expression alone is not likely to be sufficient. Specifically, expression of lower levels of transgene in line H5 [69] leads to astrocytes abnormalities (see Figs. 3, 4), while the high level expression of wild type (line I2-2) or the A30P mutant

(line O2) human α -synuclein did not impact astrocyte neurotransmission (Figs. 3, 4). In addition, increased expression of α -synuclein by astrocytes may also be a feature of PD as astrocytes generated from PD-iPSC (i.e. mutant LRRK2 cases) in the absence of neurons exhibit much higher levels of endogenous α -synuclein expression than astrocytes generated from control-iPSC cases [62]. Astrocytes can uptake α -synuclein by endocytosis and accumulate it [40] or degrade it in the lysosome [56]. Our results obtained from iSyn mice (that expresses human A53T-mutant α -synuclein only in neurons) showed no changes in astrocyte Ca^{2+} activity or SICs frequency, indicating that the changes in astrocyte-neuron communication are independent of the up-taken neuronal α -synuclein. Thus, besides taking up α -synuclein from the extracellular media for degradation, our results suggest that astrocytes express α -synuclein that regulates their intrinsic Ca^{2+} signal and gliotransmitter release.

In conclusion, present results show that the A53T point mutation in α -synuclein exacerbates astrocyte Ca^{2+} excitability and astrocyte-neuron signaling independently of neurotransmission or neuronal α -synuclein expression. Therefore, our results indicate that dysfunctions in astrocyte Ca^{2+} excitability and astrocyte-neuron signaling may contribute to the pathophysiology of α -synucleinopathies.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00401-023-02547-3>.

Acknowledgements This work was supported by National Institutes of Health-MH (R01MH119355) to PK and AA; National Institutes of Health-NINDS (R01NS097312), National Institutes of Health-NIDA (R01DA048822) to AA; National Institutes of Health-NIA (R01NS108686) to MKL and AA, National Institutes of Health (NS112540 and AG074473) to MKL, Human Frontiers Science Program (LT000827/2019-L) to AC and BBRF-Narsad to AC.

Author contributions AC designed the experiments. JP performed Ca²⁺ imaging studies. AC and CN performed slice electrophysiology studies. HM performed immunoblotting studies. SV performed immunohistochemical staining studies. AC and CN generated the figures. The first draft of the manuscript was written by AC. AA, MKL and PK contributed to critical discussion and edited the manuscript. All authors commented on the manuscript. All authors read and approved the final manuscript.

Data availability Any reasonable requests for raw data generated and analyzed for this manuscript are available from the corresponding authors upon reasonable request. TgA53T mouse line (G2-3) and SNCA-KO mice are available from Jackson lab. Other mouse lines are available from Dr. Michael Lee (mklee@umn.edu) with the execution of material transfer agreement from Johns Hopkins University and University of Minnesota.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standards The manuscript does not contain clinical studies or patient data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Angelova PR, Ludtmann MH, Horrocks MH, Negoda A, Cremades N, Klenerman D et al (2016) Ca²⁺ is a key factor in alpha-synuclein-induced neurotoxicity. *J Cell Sci* 129:1792–1801. <https://doi.org/10.1242/jcs.180737>
- Araque A, Carmignoto G, Haydon PG (2001) Dynamic signaling between astrocytes and neurons. *Annu Rev Physiol* 63:795–813. <https://doi.org/10.1146/annurev.physiol.63.1.795>
- Araque A, Carmignoto G, Haydon PG, Oliet SH, Robitaille R, Volterra A (2014) Gliotransmitters travel in time and space. *Neuron* 81:728–739. <https://doi.org/10.1016/j.neuron.2014.02.007>
- Araque A, Martin ED, Perea G, Arellano JI, Buno W (2002) Synaptically released acetylcholine evokes Ca²⁺ elevations in astrocytes in hippocampal slices. *J Neurosci* 22:2443–2450
- Araque A, Parpura V, Sanzgiri RP, Haydon PG (1999) Tripartite synapses: glia, the unacknowledged partner. *Trends Neurosci* 22:208–215
- Bartels T, Choi JG, Selkoe DJ (2011) Alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. *Nature* 477:107–110. <https://doi.org/10.1038/nature10324>
- Betzer C, Lassen LB, Olsen A, Kofoed RH, Reimer L, Gregersen E et al (2018) Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. *EMBO Rep*. <https://doi.org/10.15252/embr.201744617>
- Booth HDE, Hirst WD, Wade-Martins R (2017) The role of astrocyte dysfunction in parkinson's disease pathogenesis. *Trends Neurosci* 40:358–370. <https://doi.org/10.1016/j.tins.2017.04.001>
- Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T et al (1996) A vector for expressing foreign genes in the brains and hearts of transgenic mice. *Genet Anal* 13:159–163
- Bosson A, Boisseau S, Buisson A, Savasta M, Albriex M (2015) Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata. *Glia* 63:673–683. <https://doi.org/10.1002/glia.22777>
- Braak H, Sastre M, Del Tredici K (2007) Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. *Acta Neuropathol* 114:231–241. <https://doi.org/10.1007/s00401-007-0244-3>
- Burre J (2015) The synaptic function of alpha-synuclein. *J Parkinsons Dis* 5:699–713. <https://doi.org/10.3233/JPD-150642>
- Burre J, Sharma M, Sudhof TC (2014) Alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. *Proc Natl Acad Sci USA* 111:E4274–4283. <https://doi.org/10.1073/pnas.1416598111>
- Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. *Science* 329:1663–1667
- Buttner S, Faes L, Reichelt WN, Broeskamp F, Habernig L, Benke S et al (2013) The Ca²⁺/Mn²⁺ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to alpha-synuclein toxicity in Parkinson's disease models. *Cell Death Differ* 20:465–477. <https://doi.org/10.1038/cdd.2012.142>
- Cali T, Ottolini D, Negro A, Brini M (2012) Alpha-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. *J Biol Chem* 287:17914–17929. <https://doi.org/10.1074/jbc.M111.302794>
- Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S et al (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet* 364:1167–1169. [https://doi.org/10.1016/S0140-6736\(04\)17103-1](https://doi.org/10.1016/S0140-6736(04)17103-1)
- Covelo A, Araque A (2016) Lateral regulation of synaptic transmission by astrocytes. *Neuroscience* 323:62–66. <https://doi.org/10.1016/j.neuroscience.2015.02.036>
- Croisier E, Graeber MB (2006) Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. *Acta Neuropathol* 112:517–530. <https://doi.org/10.1007/s00401-006-0119-z>
- Delekate A, Fuchtemeier M, Schumacher T, Ulbrich C, Foddiss M, Petzold GC (2014) Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer's disease mouse model. *Nat Commun* 5:5422. <https://doi.org/10.1038/ncomms6422>
- Di Castro MA, Chuquet J, Liaudet N, Bhaukaurally K, Santello M, Bouvier D et al (2011) Local Ca²⁺ detection and modulation

- of synaptic release by astrocytes. *Nat Neurosci* 14:1276–1284. <https://doi.org/10.1038/nm.2929>
22. Durkee CA, Covelo A, Lines J, Kofuji P, Aguilar J, Araque A (2019) Gi/o protein-coupled receptors inhibit neurons but activate astrocytes and stimulate gliotransmission. *Glia*. <https://doi.org/10.1002/glia.23589>
 23. Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G (2004) Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. *Neuron* 43:729–743. <https://doi.org/10.1016/j.neuron.2004.08.011>
 24. Gomez-Gonzalo M, Martin-Fernandez M, Martinez-Murillo R, Mederos S, Hernandez-Vivanco A, Jamison S et al (2017) Neuron-astrocyte signaling is preserved in the aging brain. *Glia* 65:569–580. <https://doi.org/10.1002/glia.23112>
 25. Gomez-Gonzalo M, Zehnder T, Requisite LM, Bezzi P, Carmignoto G (2018) Insights into the release mechanism of astrocytic glutamate evoking in neurons NMDA receptor-mediated slow depolarizing inward currents. *Glia* 66:2188–2199. <https://doi.org/10.1002/glia.23473>
 26. Halassa MM, Haydon PG (2010) Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. *Annu Rev Physiol* 72:335–355. <https://doi.org/10.1146/annurev-physiol-021909-135843>
 27. Haydon PG, Carmignoto G (2006) Astrocyte control of synaptic transmission and neurovascular coupling. *Physiol Rev* 86:1009–1031. <https://doi.org/10.1152/physrev.00049.2005>
 28. Ibanez P, Bonnet AM, DeBarges B, Lohmann E, Tison F, Pollak P et al (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. *Lancet* 364:1169–1171. [https://doi.org/10.1016/S0140-6736\(04\)17104-3](https://doi.org/10.1016/S0140-6736(04)17104-3)
 29. Jiang R, Diaz-Castro B, Looger LL, Khakh BS (2016) Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington's disease model mice. *Journal Neurosci* 36:3453–3470. <https://doi.org/10.1523/JNEUROSCI.3693-15.2016>
 30. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH et al (2014) GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. *Nat Med* 20:886–896. <https://doi.org/10.1038/nm.3639>
 31. Kang J, Jiang L, Goldman SA, Nedergaard M (1998) Astrocyte-mediated potentiation of inhibitory synaptic transmission. *Nat Neurosci* 1:683–692. <https://doi.org/10.1038/3684>
 32. Kim JN, Kim MK, Cho KS, Choi CS, Park SH, Yang SI et al (2013) Valproic acid regulates α -synuclein expression through JNK pathway in rat primary astrocytes. *Biomol Ther* 21:222–228. <https://doi.org/10.4062/biomolther.2013.006>
 33. Kofuji P, Araque A (2020) G-protein-coupled receptors in astrocyte-neuron communication. *Neuroscience*. <https://doi.org/10.1016/j.neuroscience.2020.03.025>
 34. Kruger R, Kuhn W, Leenders KL, Sprengelmeyer R, Muller T, Woitalla D et al (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. *Neurology* 56:1355–1362
 35. Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ (2009) Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. *Science* 323:1211–1215. <https://doi.org/10.1126/science.1169096>
 36. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS et al (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 \rightarrow Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. *Proc Natl Acad Sci USA* 99:8968–8973. [https://doi.org/10.1073/pnas.1321975999/13/8968\[pii\]](https://doi.org/10.1073/pnas.1321975999/13/8968[pii])
 37. Li J, Uversky VN, Fink AL (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. *Biochemistry* 40:11604–11613
 38. Lieberman OJ, Choi SJ, Kanter E, Saverchenko A, Frier MD, Fiore GM et al (2017) Alpha-synuclein-dependent calcium entry underlies differential sensitivity of cultured SN and VTA dopaminergic neurons to a Parkinsonian neurotoxin. *eNeuro*. <https://doi.org/10.1523/ENEURO.0167-17.2017>
 39. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L et al (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. *Neuron* 64:807–827. <https://doi.org/10.1016/j.neuron.2009.11.006>
 40. Lindstrom V, Gustafsson G, Sanders LH, Howlett EH, Sigvardson J, Kasrayan A et al (2017) Extensive uptake of alpha-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. *Mol Cell Neurosci* 82:143–156. <https://doi.org/10.1016/j.mcn.2017.04.009>
 41. Mariotti L, Losi G, Lia A, Melone M, Chiavegato A, Gomez-Gonzalo M et al (2018) Interneuron-specific signaling evokes distinctive somatostatin-mediated responses in adult cortical astrocytes. *Nat Commun* 9:82. <https://doi.org/10.1038/s41467-017-02642-6>
 42. Martin R, Bajo-Graneras R, Moratalla R, Perea G, Araque A (2015) Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways. *Science* 349:730–734. <https://doi.org/10.1126/science.aaa7945>
 43. Moser M, Colello RJ, Pott U, Oesch B (1995) Developmental expression of the prion protein gene in glial cells. *Neuron* 14:509–517. [https://doi.org/10.1016/0896-6273\(95\)90307-0](https://doi.org/10.1016/0896-6273(95)90307-0)
 44. Navarrete M, Araque A (2008) Endocannabinoids mediate neuron-astrocyte communication. *Neuron* 57:883–893. <https://doi.org/10.1016/j.neuron.2008.01.029>
 45. Navarrete M, Araque A (2010) Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. *Neuron* 68:113–126. <https://doi.org/10.1016/j.neuron.2010.08.043>
 46. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK et al (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. *Neuron* 65:66–79. <https://doi.org/10.1016/j.neuron.2009.12.023>
 47. Nett WJ, Oloff SH, McCarthy KD (2002) Hippocampal astrocytes in situ exhibit calcium oscillations that occur independent of neuronal activity. *J Neurophysiol* 87:528–537
 48. Panatier A, Vallee J, Haber M, Murai KK, Lacaille JC, Robitaille R (2011) Astrocytes are endogenous regulators of basal transmission at central synapses. *Cell* 146:785–798. <https://doi.org/10.1016/j.cell.2011.07.022>
 49. Parri HR, Gould TM, Crunelli V (2001) Spontaneous astrocytic Ca²⁺ oscillations in situ drive NMDAR-mediated neuronal excitation. *Nat Neurosci* 4:803–812. <https://doi.org/10.1038/90507>
 50. Perea G, Araque A (2005) Properties of synaptically evoked astrocyte calcium signal reveal synaptic information processing by astrocytes. *J Neurosci* 25:2192–2203. <https://doi.org/10.1523/JNEUROSCI.3965-04.2005>
 51. Perea G, Araque A (2005) Synaptic regulation of the astrocyte calcium signal. *J Neural Transm (Vienna)* 112:127–135. <https://doi.org/10.1007/s00702-004-0170-7>
 52. Perea G, Gomez R, Mederos S, Covelo A, Ballesteros JJ, Schlosser L et al (2016) Activity-dependent switch of GABAergic inhibition into glutamatergic excitation in astrocyte-neuron networks. *Elife*. <https://doi.org/10.7554/eLife.20362>
 53. Perea G, Navarrete M, Araque A (2009) Tripartite synapses: astrocytes process and control synaptic information. *Trends Neurosci* 32:421–431. <https://doi.org/10.1016/j.tins.2009.05.001>
 54. Pirttimaki TM, Codadu NK, Awani A, Pratik P, Nagel DA, Hill EJ et al (2013) Alpha-7 Nicotinic receptor-mediated astrocytic gliotransmitter release: abeta effects in a preclinical Alzheimer's

- mouse model. PLoS ONE 8:e81828. <https://doi.org/10.1371/journal.pone.0081828>
55. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276:2045–2047
 56. Rostami J, Holmqvist S, Lindstrom V, Sigvardson J, Westermarck GT, Ingelsson M et al (2017) Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. *J Neurosci* 37:11835–11853. <https://doi.org/10.1523/JNEUROSCI.0983-17.2017>
 57. Santello M, Cali C, Bezzi P (2012) Gliotransmission and the tripartite synapse. *Adv Exp Med Biol* 970:307–331. https://doi.org/10.1007/978-3-7091-0932-8_14
 58. Schnell C, Hagos Y, Hulsmann S (2012) Active sulforhodamine 101 uptake into hippocampal astrocytes. PLoS ONE 7:e49398. <https://doi.org/10.1371/journal.pone.0049398>
 59. Shigetomi E, Bowser DN, Sofroniew MV, Khakh BS (2008) Two forms of astrocyte calcium excitability have distinct effects on NMDA receptor-mediated slow inward currents in pyramidal neurons. *J Neurosci* 28:6659–6663. <https://doi.org/10.1523/jneurosci.1717-08.2008>
 60. Singh B, Covelo A, Martell-Martinez H, Nanclares C, Sherman MA, Okematti E et al (2019) Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of alpha-synucleinopathy. *Acta Neuropathol* 138:551–574. <https://doi.org/10.1007/s00401-019-02032-w>
 61. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J et al (2003) alpha-Synuclein locus triplication causes Parkinson's disease. *Science* 302:841. <https://doi.org/10.1126/science.1090278>
 62. Sonninen T-M, Hämäläinen RH, Koskuvi M, Oksanen M, Shakirzyanova A, Wojciechowski S et al (2020) Metabolic alterations in Parkinson's disease astrocytes. *Sci Rep* 10:14474. <https://doi.org/10.1038/s41598-020-71329-8>
 63. Sorrentino ZA, Giasson BI, Chakrabarty P (2019) α -Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. *Acta Neuropathol* 138:1–21. <https://doi.org/10.1007/s00401-019-01977-2>
 64. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neurosci Lett* 251:205–208
 65. Takano T, Han X, Deane R, Zlokovic B, Nedergaard M (2007) Two-photon imaging of astrocytic Ca²⁺ signaling and the microvasculature in experimental mice models of Alzheimer's disease. *Ann N Y Acad Sci* 1097:40–50. <https://doi.org/10.1196/annals.1379.004>
 66. Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S et al (2013) A-beta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc Natl Acad Sci USA* 110:E2518–2527. <https://doi.org/10.1073/pnas.1306832110>
 67. Tanji K, Imaizumi T, Yoshida H, Mori F, Yoshimoto M, Satoh K et al (2001) Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta. *NeuroReport* 12:1909–1912. <https://doi.org/10.1097/00001756-200107030-00028>
 68. Terada S, Ishizu H, Yokota O, Tsuchiya K, Nakashima H, Ishihara T et al (2003) Glial involvement in diffuse Lewy body disease. *Acta Neuropathol* 105:163–169. <https://doi.org/10.1007/s00401-002-0622-9>
 69. Teravskis PJ, Covelo A, Miller EC, Singh B, Martell-Martinez HA, Benneyworth MA et al (2018) A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes. *J Neurosci* 38:9754–9767. <https://doi.org/10.1523/jneurosci.0344-18.2018>
 70. Volterra A, Liaudet N, Savtchouk I (2014) Astrocyte Ca²⁺(+) signalling: an unexpected complexity. *Nat Rev Neurosci* 15:327–335. <https://doi.org/10.1038/nrn3725>
 71. Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. *Nat Rev Neurosci* 6:626–640. <https://doi.org/10.1038/nrn1722>
 72. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I et al (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann Neurol* 55:164–173. <https://doi.org/10.1002/ana.10795>
 73. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keefe S et al (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci* 34:11929–11947. <https://doi.org/10.1523/jneurosci.1860-14.2014>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.